Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease
Open Access
- 6 September 2017
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 5 (1) , 1-19
Abstract
Pompe disease is a lysosomal storage disorder caused by acid-α-glucosidase (GAA) deficiency, leading to glycogen storage. The disease manifests as a fatal cardiomyopathy in infantile form. Enzyme replacement therapy (ERT) has recently prolonged the lifespan of these patients, revealing a new natural history. The neurologic phenotype and the persistence of selective muscular weakness in some patients could be attributed to the central nervous system (CNS) storage uncorrected by ERT. GAA-KO 6neo/6neo mice were treated with a single intrathecal administration of adeno-associated recombinant vector (AAV) mediated gene transfer of human GAA at 1 month and their neurologic, neuromuscular, and cardiac function was assessed for 1 year. We demonstrate a significant functional neurologic correction in treated animals from 4 months onward, a neuromuscular improvement from 9 months onward, and a correction of the hypertrophic cardiomyopathy at 12 months. The regions most affected by the disease i.e. the brainstem, spinal cord, and the left cardiac ventricular wall all show enzymatic, biochemical and histological correction. Muscle glycogen storage is not affected by the treatment, thus suggesting that the restoration of muscle functionality is directly related to the CNS correction. This unprecedented global and long-term CNS and cardiac cure offer new perspectives for the management of patients.Keywords
This publication has 72 references indexed in Scilit:
- Transcriptome assessment of the Pompe (Gaa−/−) mouse spinal cord indicates widespread neuropathologyPhysiological Genomics, 2016
- CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapyGenetics in Medicine, 2015
- Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose–response Study in Mice and Nonhuman PrimatesMolecular Therapy, 2015
- Intrapleural Administration of AAV9 Improves Neural and Cardiorespiratory Function in Pompe DiseaseMolecular Therapy, 2013
- Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyJournal of Clinical Investigation, 2013
- Teaching toleranceHuman Vaccines & Immunotherapeutics, 2012
- Adjunctive β2‐agonists reverse neuromuscular involvement in murine Pompe diseaseThe FASEB Journal, 2012
- The new era of Pompe disease: Advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and managementAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2012
- Brain Development in Infantile-Onset Pompe Disease Treated by Enzyme Replacement TherapyPediatric Research, 2006
- Impact of Humoral Immune Response on Distribution and Efficacy of Recombinant Adeno-Associated Virus-Derived Acid α-Glucosidase in a Model of Glycogen Storage Disease Type IIHuman Gene Therapy, 2005